Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)

Trial ID or NCT#

NCT06855628

Status

not recruiting iconNOT RECRUITING

Purpose

The goal of this study is to evaluate the prognostic capacity of DMI in a trial assessing the efficacy of adding BPM31510, a lipid nano dispersion of CoQ10 to standard treatment of Glioblastoma (GBM).

Official Title

Assessment Of A Novel Metabolic Imaging Modalities As A Predictor Of Therapeutic Efficacy In Glioblastoma (GBM)

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Lawrence D Recht
Lawrence D Recht
Neuro-oncologist
Professor of Neurology and Neurological Sciences (Adult Neurology) and, by courtesy, of Neurosurgery

Contact us to find out if this trial is right for you.

Contact

Lewis Naya
650-725-0379

View on ClinicalTrials.gov